859213-40-4

Basic information

• Product Name: 4-(bromomethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide
• Synonyms: 4-(bromomethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide
• CAS NO: 859213-40-4
• Molecular Weight: 543.346
• Mol File: 859213-40-4.mol

Chemical Properties

• CAS DataBase Reference: 4-(bromomethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(bromomethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide(859213-40-4)
• EPA Substance Registry System: 4-(bromomethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide(859213-40-4)

Safety Data

• Hazardous Substances Data: 859213-40-4(Hazardous Substances Data)

Upstream product

• 859213-39-1 4-(bromomethyl)-3-(trifluoromethyl)benzoic acid 
• 261952-01-6 4-methyl-3-(trifluoromethyl)benzoic acid 
• 948553-14-8 4-(bromomethyl)-3-(trifluoromethyl)benzoyl chloride 
• 641615-36-3 N₁-([4,5'-bipyrimidin]-2-yl)-6-methylbenzene-1,3-diamine 

Downstream Products

• 859217-05-3 4-[(R)-3-(dimethylamino)pyrrolidin-1-ylmethyl]-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide 
• 859217-05-3 Bafetinib 
• 641614-88-2 4-(4-methylpiperazin-1-ylmethyl)-3-trifluoromethyl-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide 

Relevant articles and documents

Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors

A series of 3-substituted benzamide derivatives structurally related to STI-571 (imatinib mesylate), a Bcr-Abl tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML), was prepared and evaluated for antiproliferative activity against the Bc

AMIDE DERIVATIVE AND MEDICINE

The present invention is directed to an amide derivative having excellent BCR-ABL tyrosine kinase inhibitory activity, or a salt thereof. The present invention provides an amide derivative represented by the following general formula [1]: (wherein R1 represents -CH2-R11, etc.; R2 represents alkyl, halogen, haloalkyl, etc.; R3 represents hydrogen, etc.; Het1 represents a group of the formula [6] as above, etc.; and Het2 represents pyrimidinyl, etc.), or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an active ingredient. The compound of the present invention is useful as a BCR-ABL tyrosine kinase inhibitor.